Primary tumour iodine avidity in relation to uptake in persistent metastatic disease in papillary and poorly differentiated thyroid cancer.

导出 OA

翻译打印收藏纠错

作者： Joachim N,Nilsson ^[1] ; Per,Grybäck ^[2] ; C Christofer,Juhlin ^[3] ; Christel,Hedman ^[4] ; Catharina Ihre,Lundgren ^[5]

作者单位： Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. joachim.nilsson@ki.se. ^[1] Department of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden. joachim.nilsson@ki.se. ^[2] Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. ^[3] Department of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden. ^[4] Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. ^[5] Department of Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden. ^[6] Stockholms Sjukhem Foundation's Research and Development Department, Stockholm, Sweden. ^[7] Division of Palliative Care, Department of Clinical Sciences, Lund University, Lund, Sweden. ^[8] Department of Breast, Endocrine Tumours and Sarcoma, Karolinska University Hospital, Stockholm, Sweden. ^[9]

关键词 Iodine avidity Papillary thyroid cancer Poorly differentiated thyroid cancer Radioiodine therapy